Larotrectinib / LOXO-101

Target: Trk family | Disease State: Cancer

Introduction / Brief Description

In July 2013, Array initiated a multi-year license and collaboration agreement with Loxo Oncology for certain Array-invented compounds targeted at the Trk family of receptors, including Larotrectinib / LOXO-101, which is currently in a Phase 2 registration trial in patients with cancer. In addition, Loxo is advancing LOXO-292, a Ret inhibitor and LOXO-195, a Trk inhibitor, in Phase 1 trials. There is a growing body of scientific literature implicating Trk alterations in diverse tumor types, including neuroblastoma and lung, thyroid and breast cancer. Many downstream pathways important in cancer are stimulated by activated Trk, such as the PI3-kinase and MAP-kinase pathways. Drugs targeting these pathways have generated responses in both solid and hematologic tumors.

Loxo will fund Array’s research and will be responsible for target selection and conducting clinical trials. Array has earned $7 million in milestone payment for the advancement of the programs. Array is eligible to receive up to $429 million in additional milestone payments and to receive royalties on sales of any resulting drugs. 

Clinical Trials

To learn more about larotrectinib clinical trials, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials only.